Response to letter entitled: Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design
- PMID: 37574396
- DOI: 10.1016/j.ejca.2023.112980
Response to letter entitled: Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment on
-
Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.Eur J Cancer. 2023 Jul;187:124-133. doi: 10.1016/j.ejca.2023.03.039. Epub 2023 Apr 7. Eur J Cancer. 2023. PMID: 37149961 Clinical Trial.
-
Re: Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.Eur J Cancer. 2023 Sep;191:112979. doi: 10.1016/j.ejca.2023.112979. Epub 2023 Jul 31. Eur J Cancer. 2023. PMID: 37532597 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical